On July 19, 2022, Novartis reported Q2 sales of $12.8 billion (a decrease of 1.4% year-over-year, a +5% constant currency growth) on core earnings per share (EPS) of $1.56.
Summary: Novartis’s Q2 2022 sales declined 1.4% as compared to the same period in 2021. Novartis reports its sales across two segments: Innovative Medicines and Sandoz.
The company reported an core operating income of $4.27 billion during Q2 2022, a year-over-year decrease of 2%. On the bottom line, the company reported a EPS of $0.77, whereas the core earnings came to $1.56 per share.
Guidance: Novartis’ guidance for the full year 2022 (in constant currency):
United States of America
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward